Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118558) titled 'Exploring the value of T2WI signal intensity index in detecting prostate cancer in patients with peripheral zone PI-RADS (v2.1) >=3' on Feb. 8.
Study Type: Diagnostic test
Study Design:
Diagnostic test for accuracy
Primary Sponsor: Wuhan Fourth Hospital
Condition:
Prostate cancer
Intervention:
Gold Standard:Ultrasound-guided systematic needle biopsy
Recruitment Status: Not Recruiting
Phase: Retrospective study
Date of First Enrollment: 2025-08-01
Target Sample Size: Target condition:83;Difficult condition:0
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.htm...